-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the past week (August 2-9), Rhine Bio, Qianhong Pharmaceutical, Zhongsheng Pharmaceutical, Xuantai Pharmaceutical, Tomson By-Health, Jiuzhou Pharmaceutical, Mengke Pharmaceutical, Haite Bio, Shanhe Pharmaceutical, Health More than 10 pharmaceutical companies in Chen Pharmaceutical released their results announcements for the first half of 202 Among them, multi-pharmaceutical companies such as Rhine Biotech and Qianhong Pharmaceutical have doubled their net prof.
In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 471%; net profit of 133 million yuan, a year-on-year increase of 1262%, exceeding the net profit of last year; non-net profit of 112 million yuan, a year-on-year increase 2197%, and profitability accelerat.
Rhine Biotech said that in the first half of 2022, the plant extraction industry is booming, the domestic and foreign demand for "sugar reduction and sugar-free" continues to grow, and the company's production and sales continue to grow rapid.
During the reporting period, the company continued to strengthen the market development of major products such as natural sweeteners and tea extrac.
Through internal technological transformation, it strengthened its cost control capabilities and rapidly improved its endogenous growth moment.
It is expected to accelerate the growth of the company's performance and build the company's second performance growth po.
Qianhong Pharmaceutical’s net profit increased by 26 times In the first half of 2022, Qianhong Pharmaceutical’s operating income increased by 323% year-on-year to 14 billion yuan; the net profit before non-deduction attributable to shareholders of listed companies increased by 1242% year-on-year to 202 million yuan; Net profit after non-deduction increased by 721% year-on-year to 147 million yu.
In the first half of 2022, 97% of Qianhong Pharma's revenue came from biopharmaceuticals, and 3% of its revenue came from other products; if divided by product, 48% of the company's revenue came from the API series, and 59% of its revenue came from the prepared drug seri.
Regarding the sharp increase in performance in the first half of the year, Qianhong Pharmaceutical once explained that the company's main business has developed well, and all businesses have increased compared with the same period last ye.
In addition, in the first half of 2022, the company received 57178 million yuan of expropriation compensation for the purchase of commercial housing in Changzhou South Square Garden
Haite Bio’s net profit increased by 61 tim.
In the first half of 2022, Haite Bio’s operating income increased by 769% year-on-year to 387 million yuan; net profit increased by 1649% year-on-year to 1872 million yu.
During the reporting period, Haite Bio achieved two-wheel drive, with mouse nerve growth factor for injection of national class I new drugs as its main product, achieved performance-driven, continuously enriched the pipeline of innovative drugs, and promoted the sustainable development of the company with innovative biological drugs; a wholly-owned subsidiary, Tianjin Han Kanghe Jingmen Hanrui takes small molecule CRO and CDMO as its main business, and actively expands customers at home and abroad, with rapid business growth and sufficient orders in hand to achieve the company's performance-driv.
Jiuzhou Pharmaceutical's half-year net profit increased by 7
In the first half of 2022, Jiuzhou Pharmaceutical's operating income increased by 515% year-on-year to 954 billion yuan; the net profit attributable to shareholders of listed companies increased by 731% year-on-year to 468 million yuan; Realized non-net profit increased by 937% year-on-year to 468 million yu.
Regarding the growth in performance, Jiuzhou Pharmaceutical said that the company continued to strengthen its CDMO business capabilities, continued to optimize its internal operation management system, improved the project operation-oriented matrix management model, continued to improve lean management, and further improved its profitabili.
According to the semi-annual report, Jiuzhou Pharmaceutical has 23 CDMO projects listed in the first half of the year, 55 Phase III clinical projects, and 662 Phase I and II clinical trials, covering anti-tumor, anti-heart failure, anti-virus, Therapeutic areas such as central nervous system and cardiovascular and cerebrovascul.
In addition, the number of new drug projects for which companies have submitted NDAs has increased significant.
Kangyuan Pharmaceutical's net profit increased by 335% In the first half of 2022, Kangyuan Pharmaceutical's operating income increased by 154% year-on-year to 097 billion yuan; the net profit attributable to shareholders of listed companies increased by 335% year-on-year to 211 million yuan
It is reported that during the reporting period, Kangyuan Pharmaceutical has comprehensively developed seven basic drug varieties and key varieties, and insisted on creating strategic varieti.
Jinzhen Oral Liquid, Xingbei Zhike Granules, Shenwu Yishen Tablets and other varieties have achieved rapid grow.
Growth; grasping the dividends of the basic drug policy, focusing on promoting the volume and variety coverage of primary medical terminals, and achieving an increase in the sales scale of primary medical terminals during the reporting period; during the reporting period, the company's non-self-operated core varieties also showed relatively good grow.
situati.
Sunward Pharmaceutical's net profit increased by 221% In the first half of 2022, Sunward's operating income increased by 182% year-on-year to 360 million yuan; net profit increased by 221% year-on-year to 6159 million yu.
It is reported that in terms of R&D innovation, Sunward Pharmaceuticals successfully developed injection-grade excipients in the first half of this year, which further enriched the company's product li.
At the same time, the Shanhe pharmaceutical auxiliary industrialization construction project was also carried out in an orderly manner in the first half of the ye.
At present, the construction of the "Phase I Project of New Pharmaceutical Excipients Production Base" located in the Pharmaceutical and Chemical Park of Huainan Economic and Technological Development Zone is continui.
The project is scheduled to be put into operation in 202 After the project is completed, it will increase the supply of high-end excipients by 9,000 to.
Zhongsheng Pharmaceutical's revenue continued to grow In the first half of 2022, Zhongsheng Pharmaceutical achieved a year-on-year increase of 57% in operating income to 1,325,858,700 yuan; realized a year-on-year decrease of 45% in non-net profit attributable to the parent, to 187,830,400 yuan; R&D investment increased year-on-year 225%, amounting to RMB 84389 milli.
The company stated that the main reason for the year-on-year decrease in net profit after non-deduction was the continuous advancement of the strategy in the reporting period, the implementation of the restricted stock incentive plan, the employee stock ownership plan, and the confirmation of share-based payment expenses and the increase in R&D investme.
It is understood that the main business line of Zhongsheng Pharmaceutical is cle.
According to the annual business theme based on traditional Chinese medicine and led by innovation, the main business has a stable development momentum and many bright spo.
Among the existing product lines of Zhongsheng Pharmaceutical, Chinese patent medicine is its core business foundation and an important source of grow.
In the first half of the year, the sales of proprietary Chinese medicines of Zhongsheng Pharmaceutical increased by 77% year-on-year to 850486 million yuan, accounting for 633% of the reven.
.
By-Health's revenue was flat year-on-year In the first half of 2022, By-Health achieved revenue of 221 billion yuan, basically flat year-on-ye.
According to the semi-annual report, BY-HEALTH's "Life-Space" brand performed well: "Life-Space" domestic products achieved revenue of 177 million yuan, a year-on-year increase of 469%; overseas business LSG operating income was 81 million Australian dollars, a year-on-year increase of 369% , the Australian market has grown steadily, and the brand image of professional probiotics has been further improv.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In the first half of 2022, the company achieved revenue of 642 million yuan, a year-on-year increase of 471%; net profit of 133 million yuan, a year-on-year increase of 1262%, exceeding the net profit of last year; non-net profit of 112 million yuan, a year-on-year increase 2197%, and profitability accelerat.
Rhine Biotech said that in the first half of 2022, the plant extraction industry is booming, the domestic and foreign demand for "sugar reduction and sugar-free" continues to grow, and the company's production and sales continue to grow rapid.
During the reporting period, the company continued to strengthen the market development of major products such as natural sweeteners and tea extrac.
Through internal technological transformation, it strengthened its cost control capabilities and rapidly improved its endogenous growth moment.
It is expected to accelerate the growth of the company's performance and build the company's second performance growth po.
Qianhong Pharmaceutical’s net profit increased by 26 times In the first half of 2022, Qianhong Pharmaceutical’s operating income increased by 323% year-on-year to 14 billion yuan; the net profit before non-deduction attributable to shareholders of listed companies increased by 1242% year-on-year to 202 million yuan; Net profit after non-deduction increased by 721% year-on-year to 147 million yu.
In the first half of 2022, 97% of Qianhong Pharma's revenue came from biopharmaceuticals, and 3% of its revenue came from other products; if divided by product, 48% of the company's revenue came from the API series, and 59% of its revenue came from the prepared drug seri.
Regarding the sharp increase in performance in the first half of the year, Qianhong Pharmaceutical once explained that the company's main business has developed well, and all businesses have increased compared with the same period last ye.
In addition, in the first half of 2022, the company received 57178 million yuan of expropriation compensation for the purchase of commercial housing in Changzhou South Square Garden
Haite Bio’s net profit increased by 61 tim.
In the first half of 2022, Haite Bio’s operating income increased by 769% year-on-year to 387 million yuan; net profit increased by 1649% year-on-year to 1872 million yu.
During the reporting period, Haite Bio achieved two-wheel drive, with mouse nerve growth factor for injection of national class I new drugs as its main product, achieved performance-driven, continuously enriched the pipeline of innovative drugs, and promoted the sustainable development of the company with innovative biological drugs; a wholly-owned subsidiary, Tianjin Han Kanghe Jingmen Hanrui takes small molecule CRO and CDMO as its main business, and actively expands customers at home and abroad, with rapid business growth and sufficient orders in hand to achieve the company's performance-driv.
Jiuzhou Pharmaceutical's half-year net profit increased by 7
In the first half of 2022, Jiuzhou Pharmaceutical's operating income increased by 515% year-on-year to 954 billion yuan; the net profit attributable to shareholders of listed companies increased by 731% year-on-year to 468 million yuan; Realized non-net profit increased by 937% year-on-year to 468 million yu.
Regarding the growth in performance, Jiuzhou Pharmaceutical said that the company continued to strengthen its CDMO business capabilities, continued to optimize its internal operation management system, improved the project operation-oriented matrix management model, continued to improve lean management, and further improved its profitabili.
According to the semi-annual report, Jiuzhou Pharmaceutical has 23 CDMO projects listed in the first half of the year, 55 Phase III clinical projects, and 662 Phase I and II clinical trials, covering anti-tumor, anti-heart failure, anti-virus, Therapeutic areas such as central nervous system and cardiovascular and cerebrovascul.
In addition, the number of new drug projects for which companies have submitted NDAs has increased significant.
Kangyuan Pharmaceutical's net profit increased by 335% In the first half of 2022, Kangyuan Pharmaceutical's operating income increased by 154% year-on-year to 097 billion yuan; the net profit attributable to shareholders of listed companies increased by 335% year-on-year to 211 million yuan
It is reported that during the reporting period, Kangyuan Pharmaceutical has comprehensively developed seven basic drug varieties and key varieties, and insisted on creating strategic varieti.
Jinzhen Oral Liquid, Xingbei Zhike Granules, Shenwu Yishen Tablets and other varieties have achieved rapid grow.
Growth; grasping the dividends of the basic drug policy, focusing on promoting the volume and variety coverage of primary medical terminals, and achieving an increase in the sales scale of primary medical terminals during the reporting period; during the reporting period, the company's non-self-operated core varieties also showed relatively good grow.
situati.
Sunward Pharmaceutical's net profit increased by 221% In the first half of 2022, Sunward's operating income increased by 182% year-on-year to 360 million yuan; net profit increased by 221% year-on-year to 6159 million yu.
It is reported that in terms of R&D innovation, Sunward Pharmaceuticals successfully developed injection-grade excipients in the first half of this year, which further enriched the company's product li.
At the same time, the Shanhe pharmaceutical auxiliary industrialization construction project was also carried out in an orderly manner in the first half of the ye.
At present, the construction of the "Phase I Project of New Pharmaceutical Excipients Production Base" located in the Pharmaceutical and Chemical Park of Huainan Economic and Technological Development Zone is continui.
The project is scheduled to be put into operation in 202 After the project is completed, it will increase the supply of high-end excipients by 9,000 to.
Zhongsheng Pharmaceutical's revenue continued to grow In the first half of 2022, Zhongsheng Pharmaceutical achieved a year-on-year increase of 57% in operating income to 1,325,858,700 yuan; realized a year-on-year decrease of 45% in non-net profit attributable to the parent, to 187,830,400 yuan; R&D investment increased year-on-year 225%, amounting to RMB 84389 milli.
The company stated that the main reason for the year-on-year decrease in net profit after non-deduction was the continuous advancement of the strategy in the reporting period, the implementation of the restricted stock incentive plan, the employee stock ownership plan, and the confirmation of share-based payment expenses and the increase in R&D investme.
It is understood that the main business line of Zhongsheng Pharmaceutical is cle.
According to the annual business theme based on traditional Chinese medicine and led by innovation, the main business has a stable development momentum and many bright spo.
Among the existing product lines of Zhongsheng Pharmaceutical, Chinese patent medicine is its core business foundation and an important source of grow.
In the first half of the year, the sales of proprietary Chinese medicines of Zhongsheng Pharmaceutical increased by 77% year-on-year to 850486 million yuan, accounting for 633% of the reven.
.
By-Health's revenue was flat year-on-year In the first half of 2022, By-Health achieved revenue of 221 billion yuan, basically flat year-on-ye.
According to the semi-annual report, BY-HEALTH's "Life-Space" brand performed well: "Life-Space" domestic products achieved revenue of 177 million yuan, a year-on-year increase of 469%; overseas business LSG operating income was 81 million Australian dollars, a year-on-year increase of 369% , the Australian market has grown steadily, and the brand image of professional probiotics has been further improv.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
